Get the Stockscreener App
69.23
5.53%
3.63
After Hours:
69.70
0.47
+0.68%
Overview
News
Price History
Option Chain
Why NVO Down?
Discussions
Forecast
Stock Split
Dividend History
Novo Nordisk Adr stock is traded at $69.23, with a volume of 13.44M.
It is up +5.53% in the last 24 hours and up +1.45% over the past month.
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
See More
Previous Close:
$65.60
Open:
$69.75
24h Volume:
13.44M
Relative Volume:
1.55
Market Cap:
$275.58B
Revenue:
$42.09B
Net Income/Loss:
$14.65B
P/E Ratio:
21.09
EPS:
3.2833
Net Cash Flow:
$10.11B
1W Performance:
+11.52%
1M Performance:
+1.45%
6M Performance:
-38.15%
1Y Performance:
-44.18%
1-Day Range:
$68.53
$69.86
1-Week Range:
$61.97
$69.86
52-Week Range:
$57.00
$148.15
Novo Nordisk Adr Stock (NVO) Company Profile
Name
Novo Nordisk Adr
Sector
Industry
Phone
-
Address
-
Compare NVO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NVO
Novo Nordisk Adr
|
69.23 | 275.58B | 42.09B | 14.65B | 10.11B | 3.2833 |
|
LLY
Lilly Eli Co
|
823.62 | 713.24B | 49.00B | 11.11B | -1.27B | 12.29 |
|
JNJ
Johnson Johnson
|
156.12 | 370.90B | 89.33B | 21.81B | 18.57B | 8.99 |
|
ABBV
Abbvie Inc
|
198.47 | 329.14B | 57.37B | 4.20B | 17.83B | 2.35 |
|
NVS
Novartis Ag Adr
|
114.29 | 221.49B | 53.22B | 12.86B | 14.85B | 6.39 |
Novo Nordisk Adr Stock (NVO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-17-25 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Mar-13-25 | Upgrade | Kepler | Hold → Buy |
| Mar-03-25 | Downgrade | Stifel | Buy → Hold |
| Feb-12-25 | Initiated | Morgan Stanley | Equal-Weight |
| Jan-06-25 | Upgrade | Bernstein | Underperform → Mkt Perform |
| May-30-24 | Initiated | Goldman | Buy |
| Apr-12-24 | Initiated | BMO Capital Markets | Outperform |
| Jan-23-24 | Initiated | Morgan Stanley | Overweight |
| Jan-16-24 | Resumed | UBS | Neutral |
| Dec-01-23 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-02-23 | Initiated | Argus | Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Jul-15-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-28-22 | Downgrade | UBS | Neutral → Sell |
| Jun-27-22 | Upgrade | Exane BNP Paribas | Underperform → Neutral |
| Jun-07-22 | Upgrade | JP Morgan | Neutral → Overweight |
| May-31-22 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-25-22 | Upgrade | Cowen | Market Perform → Outperform |
| Apr-12-22 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Mar-16-22 | Upgrade | Deutsche Bank | Hold → Buy |
| Jan-25-22 | Downgrade | Liberum | Hold → Sell |
| Dec-20-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-17-21 | Downgrade | Deutsche Bank | Buy → Hold |
| Jan-20-21 | Downgrade | Credit Suisse | Outperform → Neutral |
| Jan-15-21 | Initiated | Deutsche Bank | Buy |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Jul-06-20 | Downgrade | BofA Securities | Buy → Neutral |
| May-11-20 | Downgrade | UBS | Buy → Neutral |
| May-04-20 | Initiated | Cowen | Market Perform |
| Mar-16-20 | Upgrade | BofA/Merrill | Neutral → Buy |
| Jan-03-20 | Downgrade | Guggenheim | Buy → Neutral |
| Nov-18-19 | Upgrade | Barclays | Equal Weight → Overweight |
| Sep-17-19 | Upgrade | Citigroup | Neutral → Buy |
| Aug-30-19 | Downgrade | Jefferies | Hold → Underperform |
| Jun-20-19 | Downgrade | Deutsche Bank | Buy → Hold |
| Jun-11-19 | Upgrade | Barclays | Underweight → Equal Weight |
| Apr-29-19 | Upgrade | Credit Suisse | Neutral → Outperform |
| Jan-29-19 | Initiated | Exane BNP Paribas | Outperform |
| Dec-11-18 | Resumed | Jefferies | Hold |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Dec-29-17 | Upgrade | JP Morgan | Underweight → Neutral |
| Dec-06-17 | Upgrade | BofA/Merrill | Neutral → Buy |
| Dec-01-17 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-25-17 | Downgrade | Exane BNP Paribas | Outperform → Neutral |
| Sep-06-17 | Upgrade | BofA/Merrill | Underperform → Neutral |
View All
Novo Nordisk Adr Stock (NVO) Latest News
Novo Nordisk Stock Price Today | NYSE: NVO Live - Investing.com
Amgen's Better Than Expected Q1 Earnings Take Backseat As Eyes Are On MariTide Obesity Data - Benzinga
European ADRs Show Strength With Genfit And Novo Nordisk Leading Gains - Finimize
Novo Nordisk ADR [NVO] Revenue clocked in at $42.09 billion, down -27.20% YTD: What’s Next? - dbtnews.com
Novo Nordisk ADR (NVO) Stock: A Year of Market Fluctuations - investchronicle.com
Novo Nordisk ADR [NVO] Investment Appeal on the Rise - knoxdaily.com
Press Release Distribution & PR Platform - ACCESS Newswire
Novo Nordisk ADR (NYSE:NVO)’s 12-Month Price Target Currently Stands At 160 - Marketing Sentinel
Stocks of Novo Nordisk ADR (NVO) are poised to climb above their peers - Sete News
An Analysis of E-Home Household Service Holdings Ltd (EJH)’s Potential Price Growth - knoxdaily.com
Taking a Closer Look At Novo Nordisk ADR (NVO) Following Its Recent Trade - knoxdaily.com
3 ‘buy the dip’ candidates with wide moats - Morningstar
Recent Insider Activity Could Benefit Vodafone Group plc ADR (VOD) - knoxdaily.com
Balance Sheet Breakdown: Novo Nordisk ADR (NVO)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - DWinneX
Novo Nordisk ADR (NVO) Stock: Uncovering a 52-Week Range and Trading Volume - investchronicle.com
European ADRs Rise As Prudential And BP Lead The Pack - Finimize
NVO Stock Quote Price and Forecast - CNN
European Equities Traded in the US as American Depositary Receipts Rise in Monday Trading - marketscreener.com
Is Novo Nordisk Stock a Buy After its Collapse? - Morningstar
Eli Lilly and Novo Nordisk: Obesity Drug Coverage in Medicare Not a Straight Path - Morningstar
Novo Nordisk ADR: Analyzing NVO Stock Trends - investchronicle.com
Novo Nordisk ADR’s: Contrasting Stock Performances in a Volatile Market - investchronicle.com
Is Novo Nordisk (NVO) the Best ADR Stock to Buy According to Hedge Funds? - Insider Monkey
Novo Nordisk’s $2B deal for obesity drug a strategic game-changer for US pharmaceutical market - Yahoo Finance
Why Novo Nordisk Stock Dipped on Thursday - Yahoo Finance
What a Covid-19 vaccine means for investors - Morningstar
Novo Nordis Share Price | NYSE: NVO Stock - Investing.com UK
Novo Nordisk Adr Stock (NVO) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.65%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):